Overview

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Status:
Recruiting

Trial end date:
2022-03-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if treatment with a study drug, durvalumab has beneficial effects in people who have recurrent ovarian clear cell cancer and to determine what effects (both good and bad) it has on them and their cancer.

Phase:

Phase 2

Details

Lead Sponsor:

National University Hospital, Singapore

Treatments:

Antibodies, Monoclonal
Durvalumab